Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium.
D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000098:blood supply / Q000201:enzymology / Q000532:radiotherapy; D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects*; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D000078183:Oxindoles; D010766:Phosphorylation; D011422:Propionates; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt; D011758:Pyrroles / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D007211:Indoles; D000078183:Oxindoles; D011422:Propionates; D011518:Proto-Oncogene Proteins; D011758:Pyrroles; C412603:orantinib; D020794:Receptor Protein-Tyrosine Kinases; C494918:AKT1 protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt